Consent given pursuant to Sections 14 and 14A for the supply of therapeutic goods specified - Merck Sharp & Dohme Australia

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, was established to regulate therapeutic goods, including medicines, medical devices, and blood products, ensuring their safety, quality, and efficacy. In addressing gaps and problems related to the quality and safety of therapeutic goods, the Act provides a comprehensive framework to maintain public health standards. One particular aspect of the Act is its provision for consent to supply therapeutic goods that do not fully comply with certain regulatory requirements, as seen in the case of Merck Sharp & Dohme Australia Pty Ltd’s application for Betamethasone (DIPROSONE) lotion. This application, approved by the Department of Health, highlights the Act’s role in balancing regulatory compliance with the practicalities of therapeutic goods supply, while maintaining overall public health protection. The consent granted under section 14 and 14A of the Therapeutic Goods Act 1989, for Betamethasone lotion that does not meet the minimum letter height requirement on the bottle label, exemplifies the Act's flexibility in managing non-compliance issues. The delegate of the Secretary, in making this consent, has imposed conditions that ensure the compromised product is supplied in registered cartons with compliant text heights, thus mitigating potential risks to consumers. This approach underscores the Act's policy objective to safeguard public health by allowing for controlled exceptions while upholding stringent quality standards for therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, including medicines, medical devices, and other related products. The Act is administered by the Therapeutic Goods Administration, which operates under the Department of Health. Section 14 and 14A of the Act provide mechanisms for granting consents to supply therapeutic goods that do not fully comply with certain requirements, such as labelling standards, provided that the non-compliance does not pose an unacceptable risk to public health and safety. The Act applies to entities and individuals involved in the supply of therapeutic goods within Australia, encompassing various industries such as pharmaceuticals, medical devices, and cosmetics. The geographic reach of the Act is national, applying across all states and territories in Australia. In the case of Merck Sharp & Dohme Australia Pty Ltd, the consent granted under the Act pertains specifically to the supply of Betamethasone (DIPROSONE) lotion that does not meet the specified text height requirements on the bottle label. The consent is subject to conditions that ensure the product is supplied in registered cartons with compliant labelling and only the specified bottle labels with reduced text height are permitted.

Key Provisions

The Therapeutic Goods Act 1989 includes specific provisions that allow for the consent of non-compliance with certain regulations for therapeutic goods, such as medicines. Section 14 and 14A provide the framework for issuing such consent, allowing the Secretary of the Department of Health to permit deviations from regulatory requirements under certain conditions. In this case, Section 14A was applied by Merck Sharp & Dohme Australia Pty Ltd to seek consent for the supply of Betamethasone (DIPROSONE) 0.47mg/mL lotion bottles that did not meet the label height requirements specified in the Therapeutic Goods Order No. 69 (TGO 69). Under Section 14A, the consent granted allows for the supply of Betamethasone lotion bottles with a letter height for parts of the bottle label less than the minimum requirement of 1.5 mm, as specified in clause 3(1)(b)(ii) of TGO 69. The consent is limited to the specific bottle labels supplied with the application, which have a text height of 1.3 mm for Directions for Use and Sponsor details. Importantly, the consent stipulates that the bottles must be supplied in their registered cartons, which comply with the text height requirements of TGO 69. This ensures that while the bottle labels themselves do not meet the full regulatory standards, the cartons in which they are supplied do adhere to the necessary compliance. The obligations imposed by the Act on parties such as Merck Sharp & Dohme Australia Pty Ltd include the requirement to apply for consent if their products do not comply with certain regulatory standards. In this instance, Merck Sharp & Dohme Australia Pty Ltd must ensure that the specific bottle labels supplied with the application do not exceed the permitted non-compliance, while the cartons must adhere to the full regulatory standards. The Act also imposes an obligation on the Secretary to carefully consider the application and set conditions that mitigate any potential risks to public health and safety arising from the non-compliance. The Therapeutic Goods Act 1989 includes provisions for offences, penalties, and consequences for breaches of its requirements. While specific penalties are not detailed in the consent notice, breaches of the Act or associated regulations generally can result in both civil and criminal penalties. Civil penalties may include fines, and in more severe cases, criminal penalties can be imposed, including imprisonment. The exact penalties depend on the nature and severity of the breach, with maximum penalties often stipulated in the relevant regulations or orders. The Act aims to ensure that therapeutic goods are safe, of high quality, and that any non-compliance is adequately managed and mitigated through consent and conditions.